Publications by authors named "Luís Hugo Duarte"

2 Publications

  • Page 1 of 1

18F-FDG PET/CT in Patients with Vulvar and Vaginal Cancer: A Preliminary Study of 20 Cases.

Acta Med Port 2021 Nov 24. Epub 2021 Nov 24.

Serviço de Medicina Nuclear. Centro Hospitalar de São João. Porto. Portugal.

Introduction: Despite the growing evidence supporting the use of 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography in cervical and ovarian malignant tumours, data on vulvar and vaginal cancer is sparse. Our aim was to assess the role of 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography in patients with vulvar and vaginal cancer.

Material And Methods: A retrospective study was conducted on a cohort of 20 patients with biopsy-proven vulvar (n = 17) and vaginal (n = 3) cancer who performed 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography, between January 2013 and April 2018. We collected the clinical data of all patients, as well as the indication for 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography, its results, and the main lesion maximum standard uptake value (SUVmax). In addition, we correlated the results of 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography with other diagnostic modalities, namely histological findings, computed tomography and magnetic resonance imaging. Patients were divided into two groups, one with newly diagnosed disease and another with recurrent disease.

Results: Six patients had newly diagnosed disease and 14 had recurrent disease. The main lesion was detected by 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography in five out of six patients with newly diagnosed disease and in all 14 patients with recurrent disease. Additional sites of 2-[F-18]-fluor-2-desoxi-D-glucose uptake were identified in inguinal and iliac lymph nodes and in distant lesions. Magnetic resonance imaging and computed tomography were performed in 12 cases. In four patients with recurrent disease, abnormalities (main lesion/ metastatic lymph nodes) identified by 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography were not detected as suspicious by computed tomography.

Discussion: In our study, 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography identified abnormalities more often than conventional computed tomography scans in recurrent disease. In comparison with histology, 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography had a sensitivity of 95% and a positive predictive value of 100% in identifying the primary tumour and the recurrent main lesion. Little data is available regarding the usefulness of 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography in the management of vulvar and vaginal cancers. The existing evidence supports a high accuracy in detecting lymph node metastases and a change of 36.0% - 61.5% in patient management. Our findings reinforce the usefulness of this technique in vulvar and vaginal cancer. Limitations of our study include its retrospective nature and the rareness of both vulvar and vaginal cancer, which leads to a small sample size and few comparative imaging tests.

Conclusion: In this preliminary study, 2-[F-18]-fluor-2-desoxi-D-glucose positron emission tomography/computed tomography demonstrated it can be a useful method in patients with vulvar and vaginal cancers, namely in defining the extent of disease and contributing to accurate staging and restaging.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.20344/amp.12510DOI Listing
November 2021

Radiation Exposure of the Members of the Public from Patients Treated with 3.7 GBq and 1.85 GBq of 131I--May We Simply Divide by 2?

Health Phys 2015 Sep;109(3):249-57

*Centro de Investigação do Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal; †Serviço de Física Médica do Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal; ‡Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313, Porto, Portugal; §Serviço de Medicina Nuclear do Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.

In this work, the dose to the members of the public from two different 131I thyroid ablation patient groups (1.85 GBq and 3.7 GBq), whose a priori programmed hospitalization time is 48 h, is compared. The possibility of allocating half of the hospitalization time (24 h) for patients treated with 1.85 GBq is evaluated, having in mind the dose to the family members after patient release. The maximum dose rate at 1 m from the patient was measured at approximately 20 min, and 24, 48, and 192 h after administration of 3.7 GBq to 70 patients and 1.85 GBq to 55 patients. A triple exponential biological decay combined with physical decay was considered. Different weighting coefficients were applied to the squared residuals, allowing improved fitting and optimization of the calculation of the effective dose received by the public, E, by integration from 24 h or 48 h to infinite. Effective dose at 1 m from patients with 3.7 GBq after being released at 48 h is similar to the case of patients treated with 1.85 GBq after being released at 24 h. The average release dose rate at 24 h due to those patients is slightly higher than those administered with 3.7 GBq released at 48 h. However, no direct correspondence in the calculated dose to the members of the public was found, indicating that different dose rate release limits could be considered in both cases. These results show that it is safe, under the latest ICRP dose limits, to schedule a 24-h hospitalization time for patients administered with 1.85 GBq.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/HP.0000000000000329DOI Listing
September 2015
-->